Latest News

Wednesday, July 18, 2018

Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear palsy (PSP). In preclini…

Read the full story

Tuesday, July 17, 2018

Stryker's Surpass Streamline Flow Diverter for Treating Intracranial Aneurysms Receives Approval

Stryker announced that the Food and Drug Administration (FDA) has granted premarket approval for the Surpass Streamline flow diverter to treat unruptured large and giant wide-neck intracranial aneurys…

Read the full story

Monday, July 16, 2018

Phase 2 Confirmatory Trial of Bryostatin-1 for Alzheimer’s Disease Enrolls First Patient

The first individual has been enrolled into a confirmatory phase 2 clinical trial of bryostatin-1 (Neurotrope, New York, NY) for the treatment of persons with Alzheimer’s disease (AD). Subjects …

Read the full story

Friday, July 13, 2018

Concussion May Bring Greater Risks for Athletes with Attention Deficit and Hyperactivity Disorder

Athletes who have attention deficit hyperactivity disorder (ADHD) may be at greater risk for persistent anxiety and depression after a concussion than people who do not have ADHD, according to a preli…

Read the full story

Friday, July 13, 2018

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatment of chronic sialorrhea, …

Read the full story

Thursday, July 12, 2018

Significant Seizure Reduction in Persons With Dravet Syndrome With ZX008 in Phase 3 Trial

Adjunctive treatment of persons with Dravet syndrom with the investigational compound, low-dose fenfluramine hydrochloride (ZX008; Zogenix, Emeryville, CA), has been shown to have a statistically sign…

Read the full story

Tuesday, July 10, 2018

Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal Neuroimaging, regarding …

Read the full story

Thursday, July 05, 2018

Positive Results for Potential Alzheimer’s Disease Treatment in Phase 2 Trial

In the first late-stage study to demonstrate potential disease modifying effects for the treatment of persons with Alzheimer’s disease, a monoclonal antibody to amyloid-ß protofibrils (BAN…

Read the full story

Tuesday, July 03, 2018

Rimegepant Provides Freedom From Pain and Other Symptoms in Phase 3 Clinical Trials

Expanded data from 2 randomized, pivotal phase 3 clinical trials of rimegepant (Biohaven, New Haven, CT), a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist was presented that…

Read the full story

Saturday, June 30, 2018

Addressing the High Impact of Migraine at Work

Initial findings from a large global migraine patient survey involving >11,000 people from 31 countries show migraine is associated with overall work and activity impairment.  The My Migraine …

Read the full story

Friday, June 29, 2018

New Dosing Formulation and Strength for Pimavanserin Approved

The Food and Drug Administration (FDA) has approved a new capsule dose formulation and a new tablet strength of pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA). Both the new dose and th…

Read the full story

Thursday, June 28, 2018

Cladribine Tablets Showing Efficacy in Clinical Trials for Patients With Highly Active Multiple Sclerosis

At the recent CMSC meeting (Nashville, May 30-June 2, 2018)- data from clinical trials from the CLARITY trial of cladribine tablets (investigational in US, marketed as Mavenclad in Europe; EMD Serono,…

Read the full story

Tuesday, June 26, 2018

New Monoclonal Antibodies Against Alpha-Synuclein Generated

ProMIS Neurosciences, Inc has announced that numerous antibodies against toxic oligomers of alpha-synuclein, implicated in Parkinson’s disease (PD) have begun the final stage of discovery. Hundr…

Read the full story

Tuesday, June 26, 2018

BrainStorm Will not Make Investigational Nurown Stem Cell Treatment Available Under Right-to-Try Legislation

BrainStorm Cell Therapeutics Inc. has announced that after careful consideration of the newly enacted right-to-try (RTT) legislation, it will not make stem-cell therapy (Nurown) available to patients …

Read the full story

Tuesday, June 26, 2018

Epidiolex Approved for Treatment of Dravet and Lennox-Gastaut Syndromes

Yesterday, the Food and Drug Administration (FDA) approved cannabidiol (CBD) oral solution (Epidiolex; GW Research, Carlsbad, CA) for the treatment of seizures associated with Lennox-Gastaut syndrome …

Read the full story
Load More